Incruse Ellipta and Insulin Glargine (U-300) Pens
Determining the interaction of Incruse Ellipta and Insulin Glargine (U-300) Pens and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: umeclidinium
Brand name: Incruse Ellipta
Synonyms: n.a.
Generic Name: insulin glargine
Brand name: Basaglar KwikPen, Lantus, Lantus Solostar Pen, Toujeo SoloStar, Lantus OptiClik Cartridge, Toujeo Max SoloStar, Lantus SoloStar
Synonyms: Insulin glargine, Insulin Glargine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Incruse Ellipta-Insulin glargine and lixisenatide
- Incruse Ellipta-Insulin glargine and lixisenatide Subcutaneous
- Incruse Ellipta-Insulin glargine, recombinant Subcutaneous
- Incruse Ellipta-Insulin glulisine
- Incruse Ellipta-Insulin Glulisine (Cartridges and Pens)
- Incruse Ellipta-Insulin Glulisine (Vials)
- Insulin Glargine (U-300) Pens-Indacaterol
- Insulin Glargine (U-300) Pens-Indacaterol and Glycopyrrolate
- Insulin Glargine (U-300) Pens-Indacaterol and glycopyrrolate Inhalation
- Insulin Glargine (U-300) Pens-Indacaterol inhalation
- Insulin Glargine (U-300) Pens-Indacaterol Maleate
- Insulin Glargine (U-300) Pens-Indapamide